Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, IO Biotech secured financing of 75 MUSD and Initaitor Pharma obtained patent for IP2018 against treatment of erectile dysfunction and depression. Furthermore, muliple companies released earnings, and more companies are reporting earnings this week.
4 of the 20 listed, Danish biotech companies published news the past week. 6 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of nearly 200%.
Company news the past week
Ascendis Pharma
No news the past week
Biosergen today released its Q2 report ahead of schedule (Link)
The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 (Today). (Link)
Cessatech
No news the past week
No news the past week
No news the past week
Evaxion Biotech
No news the past week
No news the past week
Expres2ion
No news the past week
Fluoguide
No news the past week
Genmab
No news the past week
Gubra
No news the past week
Initiator Pharma
Initiator Pharma obtains IP2018 patent in Europe for treatment of Erectile Dysfunction and Depression (Link)
IO Biotech
IO Biotech Announces 2023 Second Quarter Results (Link)
IO Biotech, Inc. Announces $75 Million Private Placement Financing (Link)
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
Synact Pharma published its interim report for Q2 2023 (Link)
ViroGates
ViroGates will announces its half-year report for H1, 2023 on 17th August 2023
Zealand Pharma
No news the past week
Y-mAbs Therapeutics
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (Link)
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a negative share price performance last week of -1.6%. Fluoguide became the best performing stock with an 17% increase without announcing any company specific news. Initiator Pharma rose 4% after securing patent in Europe for IP2018 for treatment of Erectile Dysfunction and Depression. Further, IO Biotech fell even though they secured 75 MUSD in financing at a purchase price of 2.025$ that is higher than the current share price. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 75-197%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.2% driven by the best performing companies.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
